China's Hansoh Pharma has licensed global exclusive rights for its CDH17-targeting antibody-drug conjugate (ADC) HS-20110 to Roche, excluding Greater China territories, through a USD 1.53 billion agreement comprising an USD 80 million upfront payment and up to USD 1.45 billion in development and commercialisation milestones. The candidate is undergoing global Phase I trials in colorectal cancer (CRC) and other solid tumours in China and the US, evaluating safety and preliminary efficacy. Hansoh retains rights for mainland China, Hong Kong, Macau and Taiwan with potential for tiered royalty payments on ex-China sales.

HS-20110 represents a novel approach targeting CDH17 overexpression in gastrointestinal cancers including gastric and colorectal malignancies, where limited treatment options exist for advanced stages. Roche gains a strategic asset strengthening its oncology pipeline alongside existing ADC platforms while Hansoh continues its expansion of global partnerships following previous out-licensing deals for EGFR exon 20 inhibitor and B7-H3 ADC candidates.

According to PharmCube's NextBiopharm® database, HS-20110 is ranked 7th globally in terms of development among HS-20110 ADCs. Click here to request a free trial for NextBiopharm®.